Technical Analysis for KALA - Kala Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
15.45 | -2.03% | -0.32 |
KALA closed down 2.03 percent on Tuesday, April 24, 2018, on 33 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| See historical KALA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Apr 24 | 50 DMA Resistance | Bearish | 0.00% |
| Apr 24 | Bollinger Band Squeeze | Range Contraction | 0.00% |
| Apr 24 | Stochastic Reached Oversold | Weakness | 0.00% |
| Apr 24 | Oversold Stochastic | Weakness | 0.00% |
| Apr 23 | Fell Below 50 DMA | Bearish | -2.03% |
| Apr 23 | MACD Bearish Centerline Cross | Bearish | -2.03% |
| Apr 23 | Bollinger Band Squeeze | Range Contraction | -2.03% |
| Apr 23 | Oversold Stochastic | Weakness | -2.03% |
| Apr 20 | 50 DMA Support | Bullish | -3.44% |
| Apr 20 | Bullish Engulfing | Bullish | -3.44% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-03-26
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Kala Pharmaceuticals Inc. is a United States-based company that is developing ophthalmic treatments based on the Company’s Mucosal Penetrating Product (MPP) platform. The Company’s topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film. Its product development pipeline includes a 1% formulation of loteprednol etabonate to treat post-surgical ocular inflammation and pain; a 0.25% LE-MPP formulation for dry eye, blepharitis, and retinal disease, and a topically applied receptor tyrosine kinase inhibitir (RTKi-MPP) for the treatment of wet age-related macular degeneration (AMD).
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more KALA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 26.75 |
| 52 Week Low | 11.81 |
| Average Volume | 200,751 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 15.8427 |
| 20-Day Moving Average | 16.2175 |
| 10-Day Moving Average | 16.126 |
| Average True Range | 0.8916 |
| ADX | 11.27 |
| +DI | 17.23 |
| -DI | 21.71 |
| Chandelier Exit (Long, 3 ATRs ) | 15.3952 |
| Chandelier Exit (Short, 3 ATRs ) | 17.1848 |
| Upper Bollinger Band | 17.2336 |
| Lower Bollinger Band | 15.2014 |
| Percent B (%b) | 0.12 |
| BandWidth | 12.530908 |
| MACD Line | -0.0617 |
| MACD Signal Line | 0.0828 |
| MACD Histogram | -0.1445 |
| Fundamentals | Value |
|---|---|
| Market Cap | 374.31 Million |
| Num Shares | 24.2 Million |
| EPS | -32.85 |
| Price-to-Earnings (P/E) Ratio | -0.47 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.68 | ||||
| Resistance 3 (R3) | 16.75 | 16.42 | 16.48 | ||
| Resistance 2 (R2) | 16.42 | 16.10 | 16.38 | 16.41 | |
| Resistance 1 (R1) | 15.93 | 15.91 | 15.77 | 15.86 | 16.34 |
| Pivot Point | 15.60 | 15.60 | 15.51 | 15.56 | 15.60 |
| Support 1 (S1) | 15.11 | 15.28 | 14.95 | 15.04 | 14.56 |
| Support 2 (S2) | 14.78 | 15.09 | 14.74 | 14.49 | |
| Support 3 (S3) | 14.29 | 14.78 | 14.43 | ||
| Support 4 (S4) | 14.22 |
